

## AMENDMENT

In the Specification On page 12 of the Specification, please make the following changes in the last paragraph beginning on line 23 as follows:

-- Fig. 25 shows the concentration-dependent activity of synthetic ligand polypeptide (19P2-L31 SEQ ID NO:5) to specifically promote release of arachidonic acid metabolites from CHO-19P2 cells. The synthetic peptide was dissolved in degassed distilled H<sub>2</sub>O at a final concentration of 10<sup>-3</sup>M and diluted with 0.05% BSA-HBSS to concentrations of 10<sup>-12</sup>M-10<sup>-6</sup>M. The arachidonic acid metabolite releasing activity was expressed in the measured radioactivity of [<sup>3</sup>H] arachidonic acid metabolites released in the supernatant when the dilution was added to the cells. As a result, the activity of 19P2-31 to specifically promote release of arachidonic acid metabolites from CHO-19P2 cells was found in a concentration-dependent manner.--

On page 13 of the Specification, please make the following changes in the first paragraph beginning on line 1 as follows:

--Fig. 26 shows the concentration-dependent activity of synthetic ligand polypeptide (19P2-L31(O) SEQ ID NO:5) to specifically promote release of arachidonic acid metabolites from CHO-19P2 cells. The synthetic ligand peptide was dissolved in degassed distilled H<sub>2</sub>O at a final concentration of 10<sup>-3</sup>M and diluted with 0.05% BSA-HBSS to concentrations of 10<sup>-12</sup>M-10<sup>-6</sup>M. The arachidonic acid metabolite releasing activity was expressed in the measured radioactivity of [<sup>3</sup>H] arachidonic acid metabolites released in the supernatant when the dilution was added to the cells. As a result, the activity of 19P2-L31(O) to specifically promote release of arachidonic acid metabolites from CHO-19P2 cells was found in a dose-dependent manner. --

On page 17 of the Specification, please make the following changes in the first and second paragraph beginning on line 1 as follows:

-- ligand polypeptide 19P2-L31 (SEQ ID NO:5).

Fig. 56 shows the change in prolactin secretion from primary cultured rat pituitary cells upon addition of ligand polypeptide 19P2-L31 (SEQ ID NO:5). --

On page 57 of the Specification, please make the following changes in the sixth paragraph beginning on line 26 as follows:

-- [SEQ ID NO:5] (19P2-L31) is an amino acid sequence of the bovine pituitary-derived ligand polypeptide. The amino acid sequence corresponds to 23rd to 53rd positions of the amino acid sequence of SEQ ID NO:1. --

On page 93 of the Specification, please make the following changes in the heading of Example 21 beginning on line 31 as follows:

-- [Example 21]  
Synthesis of Ser-Arg-Ala-His-Gln-His-Ser-Met-Glu-Ile-Arg-Thr-Pro-Asp-Ile-Asn-Pro-Ala-Trp-Tyr-Ala-Gly-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH<sub>2</sub> (19P2-L31) (SEQ ID NO: 5) -

On page 94 of the Specification, please make the following changes in the first paragraph of Example 21 beginning on line 1 as follows:

-- His(Bom)-Ser(Bzl)-Met-Glu(OcHex)-Ile-Arg(Tos)-Thr(Bzl)-Pro-Asp(OcHex)-Ile-Asn-Pro-Ala-Trp(CHO)-Tyr(Br-Z)-Ala-Gly-Arg(Tos)-Gly-Ile-Arg(Tos)-Pro-Val-Gly-Arg(Tos)-Phe-pMBHA-resin (SEQ ID NO: 5) --

On page 95 of the Specification, please make the following changes in the first paragraph beginning on line 1 as follows:

Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH<sub>2</sub> (19P2-L31)      (SEQ ID NO: 5) -

On page 114 of the Specification, please make the following changes in the heading of Example 37 beginning on line 5 as follows:

-- [Example 37]  
The influence of 19P2-L31 (SEQ ID NO: 5) on glucose-induced increase in plasma insulin concentration --

On page 117 of the Specification, please make the following changes in the paragraph beginning on line 27 as follows:

-- The inventors of the present invention studied the influence of 19P2-L31 (SEQ ID NO: 5) injected into the area postrema (AP) of medulla oblongata on rat blood pressure. Mature male Wistar rats (body weights at operation: ca 300 g) were anesthetized with pentobarbital 50 mg/kg i.p. and immobilized in a rat brain stereotaxic apparatus. The incisal bar was set 3.3 mm below the interoral line. The skull was exposed and a hole was drilled with a dental drill for indwelling a guide cannula. In addition, anchor screws were embedded in 2 --

On page 123 of the Specification, please make the following changes in the Heading for Example 43 beginning on line 14 as follows:

-- [Example 43]  
Preparation of rabbit anti-bovine 19P2-L31 (SEQ ID NO: 5)  
Antibodies --

On page 124 of the Specification, please make the following changes in the  
Heading for Example 44 beginning on line 31 as follows:

-- [Example 44]

Inhibitory activity of antibodies against the  
release of arachidonic acid metabolites induced by  
19P2-L31 (SEQ ID NO: 5) --

On page 126 of the Specification, please make the following changes in the  
Heading for Example 46 beginning on line 15 as follows:

-- [Example 46]

The influence of 19P2-L31 (SEQ ID NO: 5) on prolactin  
secretion from pituitary cell line RC-4B/C --

On page 127 of the Specification, please make the following changes in the  
Heading for Example 47 beginning on line 17 as follows:

-- [Example 47]

The influence of 19P2-L31 (SEQ ID NO: 5) on prolactin  
secretion from primary cultured rat pituitary cells --

On page 130 of the Specification, please make the following changes in the  
Heading for Example 49 beginning on line 6 as follows:

-- [Example 49]

The influence of 19P2-L31 (SEQ ID NO: 5) on plasma prolactin  
concentration in rats --